A significant difference emerged at the one - year primary endpoint of all - cause mortality: 14.2 percent for TAVR with CoreValve compared with 19.1 percent for surgical replacement. (sciencedaily.com)
«Stroke Care: Randomized penumbra 3 - D trial of next generation stent retriever meets primary endpoints: Data also highlight frontline effectiveness of aspiration using Penumbra System for stroke revascularization.» (sciencedaily.com)
• Study achieves primary endpoints; DG031 shown to be well - tolerated and to significantly reduce levels of leukotriene B4 and myeloperoxidase • First ever clinical trial based upon the isolation of a disease gene in a common disease (decode.com)